160 related articles for article (PubMed ID: 15218312)
1. Relationship between urokinase-type plasminogen receptor, interleukin-8 gene expression and clinicopathological features in gastric cancer.
Lee KH; Bae SH; Lee JL; Hyun MS; Kim SH; Song SK; Kim HS
Oncology; 2004; 66(3):210-7. PubMed ID: 15218312
[TBL] [Abstract][Full Text] [Related]
2. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
[TBL] [Abstract][Full Text] [Related]
3. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system.
Lee DH; Yang Y; Lee SJ; Kim KY; Koo TH; Shin SM; Song KS; Lee YH; Kim YJ; Lee JJ; Choi I; Lee JH
Cancer Res; 2003 Aug; 63(15):4648-55. PubMed ID: 12907645
[TBL] [Abstract][Full Text] [Related]
4. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma.
Cho JY; Chung HC; Noh SH; Roh JK; Min JS; Kim BS
Cancer; 1997 Mar; 79(5):878-83. PubMed ID: 9041148
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
7. Tissue urokinase-type plasminogen activator receptor levels in breast cancer.
Gong SJ; Rha SY; Chung HC; Yoo NC; Roh JK; Yang WI; Lee KS; Min JS; Kim BS; Chung HC
Int J Mol Med; 2000 Sep; 6(3):301-5. PubMed ID: 10934293
[TBL] [Abstract][Full Text] [Related]
8. Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas.
Foca C; Moses EK; Quinn MA; Rice GE
Gynecol Oncol; 2000 Nov; 79(2):244-50. PubMed ID: 11063652
[TBL] [Abstract][Full Text] [Related]
9. Serine proteinase activation in esophageal cancer.
Tang WH; Friess H; Kekis PB; Martignoni ME; Fukuda A; Roggo A; Zimmerman A; Büchler MW
Anticancer Res; 2001; 21(4A):2249-58. PubMed ID: 11724279
[TBL] [Abstract][Full Text] [Related]
10. Expression of urokinase-type plasminogen activator, its receptor, and its inhibitor in gastric adenocarcinoma tissues.
Hong SI; Park IC; Son YS; Lee SH; Kim BG; Lee JI; Lee TW; Kook YH; Min YI; Hong WS
J Korean Med Sci; 1996 Feb; 11(1):33-7. PubMed ID: 8703368
[TBL] [Abstract][Full Text] [Related]
11. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
Duffy MJ; Duggan C
Clin Biochem; 2004 Jul; 37(7):541-8. PubMed ID: 15234235
[TBL] [Abstract][Full Text] [Related]
12. Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer.
Kaneko T; Konno H; Baba M; Tanaka T; Nakamura S
Cancer Sci; 2003 Jan; 94(1):43-9. PubMed ID: 12708473
[TBL] [Abstract][Full Text] [Related]
13. [The expression of urokinase-type plasminogen activator and its receptor in urinary transitional cell carcinoma].
Li YJ; Zheng BZ; Zhou ZL
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Jan; 35(1):57-9. PubMed ID: 14981816
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of stromal cell-derived urokinase-type plasminogen activator in gastric carcinoma.
Okusa Y; Ichikura T; Mochizuki H
Cancer; 1999 Mar; 85(5):1033-8. PubMed ID: 10091785
[TBL] [Abstract][Full Text] [Related]
15. Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells.
Nip J; Rabbani SA; Shibata HR; Brodt P
J Clin Invest; 1995 May; 95(5):2096-103. PubMed ID: 7537755
[TBL] [Abstract][Full Text] [Related]
16. Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma.
De Petro G; Tavian D; Copeta A; Portolani N; Giulini SM; Barlati S
Cancer Res; 1998 May; 58(10):2234-9. PubMed ID: 9605771
[TBL] [Abstract][Full Text] [Related]
17. Expression and localization of the urokinase-type plasminogen activator receptor (uPAR) in the human placenta.
Nishida Y; Hayashi Y; Imai Y; Itoh H
Kobe J Med Sci; 1998 Feb; 44(1):31-43. PubMed ID: 9846056
[TBL] [Abstract][Full Text] [Related]
18. Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role.
Plebani M; Herszènyi L; Carraro P; De Paoli M; Roveroni G; Cardin R; Tulassay Z; Naccarato R; Farinati F
Clin Exp Metastasis; 1997 Jul; 15(4):418-25. PubMed ID: 9219730
[TBL] [Abstract][Full Text] [Related]
19. [Association of uPA and uPAR expression with invasive behaviors of urinary transitional cell carcinoma].
Li YJ; Zheng BZ; Zhou ZL
Ai Zheng; 2004 Jun; 23(6):704-6. PubMed ID: 15191676
[TBL] [Abstract][Full Text] [Related]
20. Urokinase-mediated posttranscriptional regulation of urokinase-receptor expression in non small cell lung carcinoma.
Montuori N; Mattiello A; Mancini A; Taglialatela P; Caputi M; Rossi G; Ragno P
Int J Cancer; 2003 Jun; 105(3):353-60. PubMed ID: 12704669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
